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DOI: 10.1039/c2nr31064cWe present the exocytosis profile of two types of peptide-coated
nanoparticles, which have similar charge and size but different
functionality. While one kind of particles appears to progressively
exocytose, the other one has a more complex profile, suggesting that
some of the particles are re-uptaken by the cells. Both types of
particles retain their colloidal stability after exocytosis.Understanding the interactions of functional nanoparticles with
biological cells is of tremendous importance not only for new
developments in sensing, imaging and therapy but also for realizing
the fundamental cellular mechanisms and cytotoxicity of nano-
materials.1–5 With an accumulated knowledge of how the size, shape
and functionality of nanomaterials influence their fate in cells, one
should be able to synthesize nanoparticles on demand, with appro-
priate functionality and which are best suited to a particular appli-
cation. Thismeans that particles would be designed to (a) be taken up
by the cell in desirable numbers, (b) deliberately escape from the
endosomes, (c) access the cytoplasm and migrate selectively through
the cell for a given time, (d) target specific compartments and
organelles (i.e. nucleus, mitochondria) to perform desired tasks and
(e) exocytose in high numbers leaving the cell intact. Following these
aims, several research groups have successfully investigated various
aspects of interactions between functional nanoparticulate systems
and cells.6–14 For example, Brust and co-workers shed light on the
intracellular fate of spherical gold nanoparticles coated with cell
penetrating peptides and suggested ways of pre-programming
nanoparticle migration within the cytoplasm.15,16 Alternatively Mir-
kin and colleagues performed a systematic study on the internaliza-
tion rate of DNA modified gold nanoparticles and suggested new
directions for targeted gene therapy.17,18 Our group and others have
investigated how the size, shape and charge of nanoparticles influence
their cellular uptake,19–23 and how the number of endocytosed
particles correlates with the nanoparticles’ heating efficiency during
laser hyperthermia.20,24
Despite the extensive work on gold nanoparticle uptake and
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This journal is ª The Royal Society of Chemistry 2012the exocytosis of functional gold nanoparticles.26 Since gold is one of
themost promising candidates for biomedical applications in the near
future, exocytosis studies are of great importance, because they are
directly correlated with chronic cytotoxicity and nanoparticle intra-
cellular retention times.
In this paper we investigated the cellular uptake and exocytosis of
two types of peptide functionalized gold nanospheres by an
important category of mammalian cells, namely human endothelial
cells (HUVECs). The specific types of particles were chosen due to
their ease of preparation and particular function. To keep our
studies consistent, both types of nanoparticles were designed to have
similar hydrodynamic size and charge. The first batch of nano-
particles (‘inhibitors’) was functionalized with the KATWLPPR
peptide. In the past, these particles have been shown to bind to
receptors on the endothelial plasma membrane, promoting the
down-regulation of angiogenic genes.19 The second batch of nano-
particles was modified with the KPRQPSLP peptide, and they have
been employed in our previous studies as ‘mutants’ that do not
interact with known plasma membrane receptors and are simply
endocytosed.19 Thus, our work is significant because it monitors the
exocytosis of nanoparticles taking into account two important
parameters: (a) the specialized category of cells (human endothelial
cells), which participate in various critical biological processes and
(b) the types of functional nanoparticles, which, although they have
similar size and charge, undergo endocytosis in different ways; the
‘inhibitors’ via specific receptor-mediated endocytosis and the
‘mutants’ via a non-specific pathway.
A schematic illustration of the nanoparticles used in these experi-
ments is shown in Scheme 1. The functionalized particles, namely,
Pmut-OEG-NPs (for the ‘mutants’) and Pinh-OEG-NPs (for the
‘inhibitors’), have been developed following protocols described in
our previous studies.19 Briefly, gold nanospheres synthesized
according to the Turkevich method,27 with an average size of 15 
2 nm, were coated with monocarboxy (1-mercaptoundec-11-yl)
hexaethylene glycol (OEG) and coupled with peptides following an
optimized EDC/sulfo-NHS method.28
For the cellular uptake studies, endothelial cells were treated with
the particles for 4 h at 37 C, then the media was removed and the
adherent cells were washed with buffer, harvested from the culture
dish, digested and further analysed for their gold content using
ICP-AES. The results obtained from several independent ICP
measurements (see ESI†) show that the peptide coated nanoparticles
are taken up by the cells in greater numbers than the particles coated
only with OEG. We have recently reported that spherical OEG
coated nanoparticles are taken up by endothelial cells in the range ofNanoscale
Scheme 1 Schematic illustration of the nanoparticles used in the cellular
uptake and exocytosis studies. The gold nanospheres have an average size
of 15 nm. The particles are coated first with an oligoethylene glycol
derivative (OEG) and then coupled to the Pmut (KPRQPSLP) or Pinh
(KATWLPPR) peptide.
Fig. 1 Endocytosis and exocytosis profile of peptide coated nano-
particles. The cells are treated with Pmut or Pinh coated nanoparticles for
4 h, washed and incubated in fresh media for 2 h, 4 h and 6 h. The amount
of particles in the cells and outside of the cells (in the media) is estimated
in each case. The y axis value is presented as the percentage of the
particles found to be taken in by the cells after the initial 4 h treatment.
Fig. 2 Dynamic light scattering (DLS) and zeta potential measurements
of peptide-coated nanoparticles (‘inhibitors’ and ‘mutants’) before the
incubation with endothelial cells and after exocytosis.
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View Online2000 nanoparticles per cell.20 Here, when the particles are coupled to
Pinh or Pmut, a tremendous increase in nanoparticle uptake to the
order of 300 000 nanoparticles per cell is observed after 4 h of
treatment. Since the change of nanoparticle charge or size is not
significant in comparison to the OEG nanoparticles, we attribute the
difference in uptake to the peptide functionality. In the previous
work, we suggested that the Pmut coated nanoparticles are taken up
by a non-specific endocytosis pathway while the Pinh coated nano-
particles are endocytosed predominantly via a specific NRP-1
receptor-mediated pathway.19 Although, the Pinh and Pmut coated
nanoparticles are internalized following different routes, we did not
observe any large variation in the numbers of the two types of
particles found per cell after 4 h (see ESI†). This led us to an
assumption that the higher number of internalized peptide coated
particles may be attributed to the secondary interactions with the
biological medium. Indeed, the presence of the peptidesmay promote
non-specific interactions of the nanoparticles with serum proteins
resulting in an increase of nanoparticle internalization. Our group is
involved in experiments to further support this hypothesis.
A critical experiment to better understand the interactions of the
peptide-coated nanoparticles with the endothelial cells is to study the
nanoparticles’ exocytosis. For these studies the cells were treated with
the particles for 4 h at 37 C. They were then washed with buffer and
incubated in the fresh media for 2 h, 4 h or 6 h. To ensure the reli-
ability of our experiments the gold content was estimated in the cells
and in the supernatant. The experiments were performed in triplicate
and for each sample the content of gold was measured using
ICP-AES. Fig. 1 shows the nanoparticle profiles obtained for the
‘mutant’ and the ‘inhibitor’ nanoparticles.
As can be seen, in both experiments, the amount of nanoparticles
found in the cells and in the supernatant adds up to the total number
of nanoparticles initially found in the cells after 4 h of incubationwith
the particles. In case of the ‘inhibitor’ we observed that after 2 h less
than 20% of the uptaken nanoparticles are exocytosed, with a
progressive increase at 4 h and 6 h. However, most of the nano-
particles are retained in the cells for a period of 6 h. In contrast to the
‘inhibitors’, the ‘mutants’ present a different profile of exocytosis.
Although after 2 h almost 25% of the uptaken nanoparticles areNanoscalefound outside the cell, after 4 h only 10% is exocytosed. This obser-
vation is accompanied by an increase in the amount of gold nano-
particles found in the cells. After 6 h almost 40% of the ‘mutant’
particles are found to be outside the cells, in agreement with the
measurement of about 60% of particles remaining within the cells.
Overall, the comparison between the two different types of parti-
cles shows that more than half of the particles, in both cases (almost
60%), remain in the cells after 6 h. While the ‘inhibitors’ appear to
progressively exocytose, the ‘mutants’ have a more complex profile,
suggesting that some of the particles (about 10%) are re-uptaken by
the cells after 4 h. These data are supported by an increase in the
amount of ‘mutant’ particles found in the cells after 4 h. The varia-
tions in exocytosis profile between the two different types of particles
highlights the difference in the peptide capping, which is strongly
correlated with the nanoparticle uptake mechanism and the fate of
particles in the cells.
In the cell, nanoparticles are exposed to a stringent biochemical
environment, and although capped with organics, a question about
their colloidal stability when they are exocytosed remains. Therefore,
we measured the hydrodynamic diameter and the net zeta potential
of the particles prior to the exposure to the cells and 24 h after their
exocytosis. Fig. 2 shows the experimental results.
In both cases, for ‘inhibitors’ and ‘mutants’, only minor variations
are observed in the hydrodynamic diameter and zeta potential before
and after the exocytosis. These qualitative results clearly indicate
that most of the exocytosed particles retain their colloidal stability,
independently from the peptide-coating chosen here.This journal is ª The Royal Society of Chemistry 2012
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View OnlineConclusions
In conclusion, we monitored for the first time the endocytosis and
exocytosis profile of two types of peptide-coated nanoparticles
(‘mutants’ and ‘inhibitors’) of similar size and charge, which vary only
in the peptide sequence. Although the two types of particles do not
follow the same endocytosis pathways, they are taken up by the
endothelial cells in greater numbers than just pegylated particles.
They also appear to have a distinctively different exocytosis profile,
suggesting that some of the ‘mutant’ particles are re-uptaken by the
cells after 4 h, while for a period of 6 h the ‘inhibitor’ particles are
progressively exocytosed. DLS and zeta potential measurements
indicate that both types of particles retain their colloidal stability after
exocytosis.
Experimental section
Spherical gold NPs were prepared according to the well-established
citrate reductionmethod,27 and stabilised with bis(p-sulfonatophenyl)
phenyl phosphine dehydrate dipotassium salt (BSPP). Nanoparticles
were then capped with monocarboxy (1-mercaptoundec-11-yl)
hexaethylene glycol ligand, which chemisorbs directly onto the gold
surface via the thiol group, and redispersed in 0.01 M sodium borate
buffer, pH 9. The peptides were coupled following a previously
established protocol.28 Briefly, Pmut or Pinh solutions (10 ml, 1 mg
ml1,MWmut¼ 922.1, andMWinh¼ 968.2; in 0.01M sodium borate
buffer, pH 9) were added to OEG-NPs (0.5 ml, 1.5 nM; in 0.01 M
sodium borate buffer, pH 9) andmixed. To this, aqueous solutions of
coupling agents: EDC (1-(3-(dimethylamino)propyl)-3-ethyl-carbo-
diimidemethiodide, 5 ml, 0.2 M) and sulfo-NHS (N-hydroxy-
sulfosuccinimide, 10 ml, 0.2 M) were introduced. The reaction
mixtures were stirred for 24 h at room temperature. Prior to incu-
bation with cells, the functionalized particles were purified by triple
centrifugation/decantation (16 400 rpm, 15 min) and redispersed in
M199 (20% human serum) growth media.
Dynamic light scattering and the zeta potential of the functional
particles before and after exocytosis were measured with a Zetasizer
Nano ZS (Malvern Instruments Ltd). Disposable cuvettes (Malvern
Instruments Ltd) were employed in dynamic light scattering (DLS)
measurements, and disposable capillary cells in z-potential
measurements.
The total gold content in the cells and cell growth media was
measured with ICP-AES. For the uptake studies, a confluent
monolayer of HUVECs grown on a porcine gelatin (0.2% in HBSS)
pre-coated 12-well micro-plate was incubated with nanoparticles
[(1.3 ml, 8 nM), in a 20% human serum M199 growth medium)] for
4 h at 37 C in a humidified 5% CO2 balanced air incubator. After
treatment, cells were washed three times with 1 PBS and harvested
with trypsin/EDTA solution (0.5 ml, Sigma-Aldrich). In the exocy-
tosis studies, the cells, following 4 h incubation with nanoparticles,
were washed three times with 1 PBS buffer, then returned to the
incubator in 1 ml of fresh growth media for an additional 2, 4 or 6 h.
The media were then collected, while the adherent cells were
separately harvested with trypsin/EDTA.
The suspensions of the harvested cells were collected and digested
by acid prior to ICP measurements. The number of gold atoms per
nanoparticle was estimated from the average size of NPs taking intoThis journal is ª The Royal Society of Chemistry 2012account the distances between atoms in the fcc crystal structure and
the volume of a gold atom. At least three independent experiments
were performed to estimate average numbers.Acknowledgements
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